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ABSTRACT
Objectives: One of the common symptoms in patients with advanced gynecologic tumors is intestinal obstruction. Pal-
liative management may include pharmacological treatment, stenting as well as surgical removal of obstruction cause. 
Selection of appropriate treatment should be based on careful and individual assessment of advantages, disadvantages 
and possible complications. The aim of the study was to analyze the effectiveness of non-invasive treatment in patients 
with gynecologic malignancies suffering from intestinal obstruction.
Material and methods: It was a retrospective analysis of factors associated with primary non-invasive intestinal obstruc-
tion treatment effectiveness. Data were collected from medical records of 17 patients managed and followed-up in a single 
gynecologic oncology center due to endometrial cancer, fallopian tube cancer, uterine leiomyosarcoma, and ovarian cancer 
admitted to the ward because of symptomatic intestinal obstruction. Mean observation time lasted 40.6 months. Non-in-
vasive treatment included fluid therapy, dexamethasone, buscolysin, mebeverine, ranitidine, simethicone, omeprazole, 
magnesium sulphate, semi-liquid diet, and parenteral nutrition. Characteristics including age, BMI, comorbidities, oncologi-
cal treatment, histology type, stage, grade, presence of ascites, location of primary tumor and metastases were analyzed. 
Results: The number of obstruction episodes varied from 1 to 5. Mean time between multiple episodes lasted 3.2 months. 5 pa-
tients required surgical treatment. For the rest of the patients primary non-invasive treatment was sufficient.
Conclusions: Most cases of bowel obstruction in patients with advanced gynecologic malignancies can be successfully 
managed without invasive treatment. Moreover, non-invasive obstruction management can be applied multiple times in 
case of recurrence.
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INTRODUCTION
Palliative care is an integral aspect of oncological treat-
ment. Increasing the quality of life, soothing pain and 
reducing symptoms of advanced disease is crucial from 
both medical and ethical perspective [1, 2]. Selection of 
appropriate treatment should be based on careful and 
individual assessment of both advantages and disadvan-
tages of available methods, together with possible com-
plications [3–5]. Intestinal obstruction is one of the most 
common symptoms affecting even every second patient 
with advanced gynecologic tumors located in the pelvis [6]. 
Reported incidence of this complication among ovar-
ian cancer patients varies between 20 and 50% [7, 8]. 
The etiology of intestinal obstruction in this group of pa-
tients can be multifactorial — resulting from mass excess 
and intestinal infiltration, or oncological therapy side ef-
fects. Palliative management may include pharmacological 
treatment, stenting as well as surgical removal of obstruc-
tion cause. Apart from relieving the symptoms, obstruction 
treatment is vital for patient’s proper nutritional status as 
malnutrition affects over half of ovarian cancer patients 
and may develop into cancer cachexia syndrome, a di-
rect cause of death during oncological treatment [9, 10]. 
Various studies claim that in case of appropriately selected 
therapy, pharmacological and surgical treatment are simi-
larly effective [11, 12]. 
497
Joanna Kacperczyk-Bartnik et al., Intestinal obstruction in gynecologic malignancies
www. journals.viamedica.pl/ginekologia_polska
Objectives
The aim of the study was to analyze which patients with 
advanced gynecological malignancies may benefit from 
primary non-invasive treatment, and which require further 
surgical approach. 
MATERIAL AND METHODS
It was a retrospective analysis of factors associated with 
non-invasive intestinal obstruction treatment effective-
ness. Data were collected from medical records of patients 
managed and followed-up in a single 14-bed gynecologic 
oncology center. Inclusion criteria were as follows: admis-
sion to the ward caused by symptomatic intestinal obstruc-
tion and application of primary pharmacological treatment 
between 2014–2016 resulting in discharge in stable gen-
eral condition. In case of no improvement after 7 days of 
non-invasive treatment or intensification of symptoms, ini-
tially conservative treatment was considered ineffective and 
surgical approach was introduced. Exclusion criteria were: 
intestinal obstruction as a primary complaint leading to 
initial neoplasm diagnosis followed by the radical surgery. 
The non-invasive obstruction treatment protocol included 
fluid therapy, dexamethasone, buscolysin, mebeverine, ran-
itidine, simethicone, omeprazole, magnesium sulphate and 
semi-liquid diet. Patients not tolerating enteral nutrition were 
qualified for parenteral nutrition according to the European So-
ciety for Clinical Nutrition and Metabolism (ESPEN) guidelines 
[13]. Patients’ characteristics including past medical history, 
comorbidities, age at malignancy diagnosis, time from dis-
ease onset, BMI during diagnosis and each obstruction epi-
sode, body mass loss, type of applied oncological treatment, 
histology result, stage, grade, location of primary tumor and 
metastases, ascites presence, number of obstruction episodes, 
and type of obstruction management were analyzed. Mean ob-
servation time lasted 40.6 months (3–168 months). The FIGO 
(International Federation of Gynecology and Obstetrics) system 
was used for ovarian cancer, fallopian tube cancer, endometrial 
cancer and uterine sarcoma staging [14–16]. Out of 20 patients 
initially enrolled in the study, 17 met the criteria required for 
further analysis, presenting altogether 30 episodes of intestinal 
obstruction. All patients excluded from the study were diag-
nosed with serous ovarian cancer stage IIIC, grade 3 and un-
derwent radical surgery shortly after the obstruction episode.
RESULTS
Among analyzed 17 patients 1 suffered from endometrial 
cancer, 2 from fallopian tube cancer, 1 from uterine leiomyo-
sarcoma, and 13 had ovarian cancer: 10 patients serous ovar-
ian cancer, 2 patients endometrioid ovarian cancer, 1 patient 
clear-cell ovarian cancer (Fig. 1). All patients suffered from 
Figure 1. Intestinal obstruction in patients with gynecological malignancies — management and outcome
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poorly differentiated G3 tumors at stage III–IV. The num-
ber of applied chemotherapy lines varied between 1 and 
9. Because of advanced disease 3 patients were managed 
without radical oncological surgery. The number of obstruc-
tion episodes varied between 1 and 5. Mean time between 
multiple episodes lasted 3.2 months (2 weeks–22 months). 
In 5 (29.4%) patients non-invasive treatment was ineffec-
tive and additional surgical approach was required. Opera-
tional interventions included: 1 repeated debulking surgery, 
1 colostomy, and 3 adhesion removal surgeries. The rest of 
patients were successfully managed non-invasively. Patient 
treated with colostomy developed 4 obstruction episodes 
following the procedure, all of them successfully treated 
pharmacologically. Table 1. shows a comparison of patients’ 
characteristics depending on the needed therapy mode. 
Previous abdominal surgeries included Cesarean sections, 
appendectomies and cholecystectomies. 
DISCUSSION
Symptoms of over 70% of patients with stage III gyneco-
logic malignancy analyzed in this study were successfully 
relieved with supportive treatment. Because of the size of 
the studied population it is difficult to obtain statistically 
significant evidence helpful in prediction of patients at risk 
of irresponsiveness to non-invasive management. For the 
same reason the power of statistical tests was decreased. 
Nevertheless, certain clinical observations were made. 
First of all, patients with no history of radical surgical 
treatment were more likely to develop obstruction requiring 
invasive management. Similar conclusions were made by 
Bryan et al. [17] as in their study more surgical interventions 
were needed by patients who had been suboptimally de-
bulked rather than optimally. Another aspect of past surgical 
history concerns abdominal interventions performed before 
oncological diagnosis. Patients who required operational 
management more frequently had undergone a C-section, 
cholecystectomy or appendectomy in the past. In all of these 
cases intestinal obstruction was associated with massive 
abdominal adhesions. 
Another observation was made concerning the pres-
ence of ascites. In the studied group patients with recurrent 
ascites were more responsive to non-invasive obstruction 
management. This could be caused by an increased subjec-
tive feeling of obstruction and presentation of accompany-
ing symptoms in response to relatively less advanced condi-
tion due to the presence of additional fluid excess. Whatever 
the reason, this finding gives hope to patients with ascites 
as it is known to be a risk factor for poor prognostic surgery 
outcomes [18]. Therefore, initially supportive management 
in this group of patients should be preferred.
Additional consideration of obstruction management 
outcome concerns the time of observation. Patients treated 
invasively presented the first episode of obstruction sooner 
after the cancer diagnosis than patients treated successfully 
in supportive manner. On the other hand, surgical patients 
were characterized by longer observation time following the 
first obstruction symptoms, which suggests their condition 
could be more acute, but at that time less oncologically 
advanced in comparison to the group responsive to phar-
macological treatment. Of course, the etiology of indication 
for surgical treatment is essential in this context, as patients 
with adhesions are reported to present much longer interval 
in readmission for bowel obstruction than patients with ma-
lignant cause [19]. Similarly, in the study by Sartori et al. [20] 
patients who underwent surgical treatment showed better 
survival than conservatively treated group. However, op-
posite findings were presented in the study by Tran et al. as 
authors observed no statistically significant differences in 
outcome depending on the type of intervention — surgical, 
pharmacological or stent placement [21]. 
Since no official guidelines for management of intesti-
nal obstruction in oncogynecological patients have been 
proposed till date, the first-line supportive treatment var-
ies among cancer centers. In the study by Mangili et al. [7] 
Table 1. Patients’ characteristics depending on the needed therapy 
mode
Feature Non-invasive treatment (n = 12)
Invasive 
treatment (n = 5)
Ovarian cancer (%) 11 (92%) 2 (40%)
Fallopian tube cancer (%) 1 (8%) 1 (20%)
Endometrial cancer (%) 0 1 (20%)
Uterine leiomyosarcoma (%) 0 1 (20%)
Mean age at cancer 
diagnosis (years) 63.8 (48–73) 65 (59–79)
Time of observation since 
cancer diagnosis (months) 40.7 (3–168) 47 (15–120)
Time of 1st obstruction 
episode since cancer 
diagnosis (months)
39.2 (8–168) 27.8 (3–84)
Mean no. of obstruction 
episodes during 
observation
1.5 (1–3) 1.8 (1–5)
Abdominal surgeries 
before oncological 
treatment (%)
2 (17%) 3 (60%)
Ascites at cancer diagnosis (%) 9 (75%) 2 (40%)
Radical surgery (%) 11 (92%) 3 (60%)
Mean no. of chemotherapy 
lines 3.75 (1–9) 2.6 (2–4)
Anemia during 
chemotherapy treated with 
blood transfusion (%)
7 (58%) 3 (60%)
Obesity at cancer diagnosis 6 (50%) 2 (40%)
Body mass loss over 5% (%) 8 (67%) 3 (60%)
499
Joanna Kacperczyk-Bartnik et al., Intestinal obstruction in gynecologic malignancies
www. journals.viamedica.pl/ginekologia_polska
comparing medical and surgical approach, pharmacological 
treatment included different doses of octreotide. The initial 
management described by Bais et al. [22] consisted of na-
sogastric tube placement, rectal enemas and intravenous 
fluid administration, however it was always preceding the 
surgical intervention. Similar management was presented 
in the conservative treatment implemented by Suidan et al. 
[8], which included bowel rest, gastrostomy or jejunostomy 
tube placement and intravenous fluid administration — the 
surgery was performed only if the conservative treatment 
of obstruction symptoms was unsuccessful. 
CONCLUSIONS
As this study shows, most cases of bowel obstruction 
in advanced gynecologic malignancies can be successfully 
managed without invasive treatment. Individual assess-
ment of response to therapy should be applied each time in 
order to achieve symptoms relief and decide which patient 
requires more invasive approach.
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